HDAC6 and acute kidney injury: Recently, by using tubastatin A, a selective inhibitor of HDAC6, we demonstrated that HDAC6 inhibition can protect the kidney from cisplatin- or rhabdomyolysis-induced AKI (Shi et al., 2017; Tang et al., 2018), suggesting that this isoform of class IIb HDACs is involved in the pathogenesis of AKI.